AGNPFAlgernon Pharmaceuticals Inc.

About Algernon Pharmaceuticals Inc. (AGNPF)

Algernon Pharmaceuticals Inc. (AGNPF) is a Biotechnology company headquartered in Vancouver, BC, Canada whose shares trade over-the-counter on the OTCQB tier.

Algernon Pharmaceuticals is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Products and services

Algernon Pharmaceuticals is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

AGNPF key facts

Ticker symbol

AGNPF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Vancouver, BC, Canada

Country of incorporation

CA

Year of incorporation

2015

Employees

3

Estimated market cap

$1.81M (as of Apr 11, 2025)

Shares outstanding

28,657,229

Reporting standard

International Reporting: Canadian Securities Exchange

Audit status

Audited

Fiscal year end

8/31

Latest filing

Quarterly Report (Nov 30, 2024)

Algernon Pharmaceuticals Inc. leadership

• Christopher J. Moreau — CEO
• James Kinley — CFO
• Christopher Bryan — Vice President

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with A